Acquisition leverage Post-acquisition by Hologic, Endomag gains access to a larger global sales and distribution network for breast cancer technology. This opens doors to major cancer centers and regional health systems, enabling co-selling Sentimag, Magseed and Magtrace alongside Hologic's portfolio. Use this to accelerate adoption in target accounts with joint marketing and clinical case studies.

Breast conserving focus Endomag's mission to avoid unnecessary surgery aligns with hospital goals to expand breast conserving therapy and reduce reoperation rates. Target surgical oncology and breast centers seeking precise localization and mapping to improve patient outcomes, with ROI messaging around shorter OR times and downstream savings.

Global footprint Reference deployments with Hannibal Regional and Jefferson County Health Center demonstrate capability to scale across regional networks. Build a partner led expansion playbook to replicate in Midwest and other regions, leveraging awards and FT 1000 recognition as credibility in market development.

Platform expansion Magseed localization, Magtrace lymphatic mapping and Sentimag surgical guidance form a cohesive platform. Pitch cross sell opportunities to centers already using one component, and offer bundled training, service contracts, and data driven outcomes analytics to drive full platform adoption.

Regulatory edge ISO 13485 certification and quality systems underpin regulatory readiness, a key differentiator for hospitals navigating procurement cycles and regional approvals. Highlight compliance maturity to shorten decision times and support global market entry, including potential alignment with Hologic regulatory processes.